Charles River Laboratories and AstraZeneca Renew Strategic Partnership Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Charles River Laboratorie (CRL) Misses Q2 EPS by 1c; Extends Agreement with AstraZeneca (AZN)
July 30, 2015 7:13 AM EDTCharles River Laboratorie (NYSE: CRL) reported Q2 EPS of $0.96, $0.01 worse than the analyst estimate of $0.97. Revenue for the quarter came in at $339.6 million versus the consensus estimate of $338.3 million.
Charles River Laboratorie sees FY2015 EPS of $3.60-$3.70, versus the consensus of $3.64.
The company also announced announced that it has extended its initial three-year partnership with AstraZeneca (NYSE:... More
